Top Pharmaceutical Stocks To Follow Now – January 31st

AbbVie, Vertex Pharmaceuticals, Eli Lilly and Company, Thermo Fisher Scientific, and Colgate-Palmolive are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks refer to shares of publicly traded companies engaged in the research, development, manufacturing, and marketing of pharmaceutical products such as drugs and medical devices. Investors may buy or sell these stocks on financial markets to potentially profit from changes in the company’s value and performance. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV traded up $9.03 during trading hours on Friday, hitting $184.68. 6,551,023 shares of the company’s stock were exchanged, compared to its average volume of 5,935,105. AbbVie has a 1-year low of $153.58 and a 1-year high of $207.32. The stock’s 50-day moving average is $176.43 and its two-hundred day moving average is $184.84. The stock has a market cap of $326.36 billion, a price-to-earnings ratio of 64.30, a PEG ratio of 1.77 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ VRTX traded up $23.34 on Friday, hitting $461.74. 2,262,974 shares of the stock were exchanged, compared to its average volume of 1,512,317. The company has a market capitalization of $118.91 billion, a PE ratio of -231.63, a P/E/G ratio of 2.29 and a beta of 0.40. The business’s fifty day moving average is $434.34 and its 200 day moving average is $463.31. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY traded down $5.29 during trading hours on Friday, hitting $817.94. The company had a trading volume of 1,009,062 shares, compared to its average volume of 3,774,294. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a fifty day moving average of $782.29 and a 200-day moving average of $845.82. Eli Lilly and Company has a 12 month low of $637.00 and a 12 month high of $972.53. The firm has a market cap of $776.49 billion, a price-to-earnings ratio of 88.64, a PEG ratio of 1.71 and a beta of 0.41.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Thermo Fisher Scientific stock traded down $8.57 during trading hours on Friday, reaching $598.17. 1,189,794 shares of the stock were exchanged, compared to its average volume of 2,057,705. The company has a market cap of $228.80 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a 50 day moving average of $539.66 and a two-hundred day moving average of $570.59.

Colgate-Palmolive (CL)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Colgate-Palmolive stock traded down $4.78 during trading hours on Friday, reaching $86.11. 5,824,956 shares of the stock were exchanged, compared to its average volume of 5,096,266. The stock has a 50 day moving average of $91.52 and a two-hundred day moving average of $97.25. Colgate-Palmolive has a twelve month low of $82.68 and a twelve month high of $109.30. The company has a current ratio of 1.04, a quick ratio of 0.68 and a debt-to-equity ratio of 9.46. The company has a market cap of $70.35 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 3.70 and a beta of 0.44.